Stock ACRV ACRIVON THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Acrivon Therapeutics, Inc.

Equities

ACRV

US0048901096

Market Closed - Nasdaq
Other stock markets
 21:00:00 31/05/2024 BST 		5-day change 1st Jan Change
7.72 USD +1.98% Intraday chart for Acrivon Therapeutics, Inc. -2.89% +56.91%
05-14 Acrivon Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-30 North American Morning Briefing : More Earnings -2- DJ

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Acrivon Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
North American Morning Briefing : More Earnings -2-
DJ
Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress At Corporate R&D Event
CI
Top Midday Gainers
MT
Wall Street Set to Open Slightly Higher as Investors Await Wednesday's Inflation Data
MT
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Tuesday on Caution Ahead of Inflation Data
MT
Acrivon Therapeutics Announces Private Placement of 8.2 Million Shares; Shares Surge
MT
Top Premarket Gainers
MT
Acrivon Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Acrivon Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Acrivon Therapeutics, Inc. Appoints Ivana Magovcevic-Liebisch to its Board of Directors
CI
Acrivon Therapeutics, Inc. Announces U.S. Food and Drug Administration Grants Breakthrough Device Designation for ACR-368 OncoSignature Assay for Ovarian Cancer
CI
Acrivon Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Acrivon Therapeutics, Inc. Announces ACR-2316, a Novel Dual WEE1 and PKMYT1 Inhibitor Development Candidate, Designed Using Acrivon?s AP3 Platform to Achieve Potent Single Agent Activity, as Demonstrated in Preclinical Studies
CI
Acrivon Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Acrivon Therapeutics Reports Q1 Loss Narrows From Year Earlier, Receives Fast Track Designation From US FDA For Possible Cancer Therapy
MT
Acrivon Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Acrivon Therapeutics Announces FDA Grants Fast Track Designation for Development of ACR-368 in Platinum-Resistant Ovarian Cancer and Endometrial Cancer
CI
Acrivon Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Acrivon Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ACRV Stock
  4. News Acrivon Therapeutics, Inc.
  5. Highlights